Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SNTI with free AI briefings, catalyst countdowns, and dilution alerts.

SNTI · Senti Biosciences Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$13M Cash on Hand
3.6mo Cash Runway
Follow SNTI by email Get an email when SNTI reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SNTI, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Allogeneic Calibrated Release IL-15-expressing… AML/MDS Phase 1 · NCT06325748 Active not recruiting
Fludarabine Hepatocellular Carcinoma (HCC) Early Phase 1 · NCT06652243 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SNTI holds $13M in cash and short-term investments (as of Jun 30, 2026) and burns about $10.9M/quarter from operations, an estimated runway of 3.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SNTI files for a raise →

👥 Who Owns SNTI

Insiders 42.4% Other 5%+ holders 11.4% Institutions (23 holders) 19% Public and other holders 27.2%
HolderTypeShares% of sharesAs of
Celadon Partners SPV 24
10% owner
Insider 25,748,890 30.04% 2026-09-03
Celadon Partners, LLC 5%+ holder (13D) 9,777,000 11.41% 2025-03-06
BAYER HEALTHCARE LLC
10% owner · +3.33M options
Insider 6,142,848 7.17% 2026-03-27
New Enterprise Associates 15, L.P.
10% owner
Insider 3,775,615 4.41% 2026-03-27
Timothy K Lu
CEO, Director · +1.93M options
Insider 587,949 0.69% 2026-10-21
Kanya Rajangam
Pres. & Chief Med. & Dev. Off. · +284,588 options
Insider 54,890 0.06% 2026-10-21
Donald F Tang
Director · +78,350 options
Insider 10,368 0.01% 2024-12-09

Share count 85,706,263 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SNTI picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNTI and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.